Charles River Laboratories International (CRL) Projected to Post Quarterly Earnings on Wednesday

by · The Markets Daily

Charles River Laboratories International (NYSE:CRL – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $2.97 per share and revenue of $960.36 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.12 EPS. On average, analysts expect Charles River Laboratories International to post $11.38 EPS for the current fiscal year and $12.58 EPS for the next fiscal year.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $359.34 on Monday. The company has a fifty day moving average of $302.09 and a 200-day moving average of $222.34. The firm has a market capitalization of $17.15 billion, a P/E ratio of -74.09, a P/E/G ratio of 3.36 and a beta of 1.36. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International has a twelve month low of $146.20 and a twelve month high of $379.63.

Insider Buying and Selling

In related news, CAO Michael Knell sold 6,645 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James Foster sold 33,561 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $9,478,800. The trade was a 51.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 118,169 shares of company stock valued at $35,191,216. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CRL has been the topic of several research analyst reports. Robert W. Baird increased their target price on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Charles River Laboratories International in a research note on Monday, September 28th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday, August 10th. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Finally, Zacks Research raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $302.33.

Read Our Latest Report on CRL

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

Featured Stories